Selection from HEOR Bibliography
| Search criteria | ||||
| Belgium |
||||
| The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a | ||||
| Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer, Leo H. Visser, on behalf of the CONFIDENCE Study Group | ||||
| IQVIA Netherlands, Real World Evidence, Netherlands b Department of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, Netherlands c Medical University of Graz, Graz, Austria d Merck BV, Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Germany e St Elisabeth Tweesteden Hospital, Tilburg, the Netherlands | ||||
| eNeurologicalSci, Volume 28, 2022, 100409, ISSN 2405-6502, https://doi.org/10.1016/j.ensci.2022.100409. (https://www.sciencedirect.com/science/article/pii/S2405650222000181) |
||||
| , Article | ||||
| , Austria, Belgium, Netherlands , Slovakia | ||||
| Abstract: https://www.sciencedirect.com/science/article/pii/S2405650222000181 | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Drug Utlization Study, Neurological disorders | 2022 | English | , Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Prospective study | |
| Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China | ||||
| Ahmed Salem # 1, Heng Zhong # 2, Mafalda Ramos 1, Mark Lamotte 1, Hao Hu 3 | ||||
| 1Real World Evidence, IQVIA, Zaventem, Belgium. 2R&D China, AstraZeneca R&D, Shanghai, China. 3Institute of Chinese Medical Sciences, University of Macau, Macau, China haohu@um.edu.mo. #Contributed equally. | ||||
| BMJ Open 2021;11:e043664. doi:10.1136/bmjopen-2020-043664 e043664. doi:10.1136/bmjopen-2020-043664 PMID: 33910947 PMCID: PMC8094343 DOI: 10.1136/bmjopen-2020-043664 |
||||
| , Article | ||||
| , Belgium, China | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/33910947/ | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Respiratory disease | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
| A novel decision model to predict the impact of weight management interventions: The Core Obesity Model. | ||||
| Sandra Lopes 1, Henrik H Meincke 1, Mark Lamotte 2, Anamaria-Vera Olivieri 3, Michael E J Lean 4 | ||||
| 1Novo Nordisk A/S Søborg Denmark. 2IQVIA Zaventem Belgium. 3IQVIA Basel Switzerland. 4Human Nutrition School of Medicine, Dentistry and Nursing Royal Infirmary University of Glasgow Glasgow UK. | ||||
| Obesity Science & Practice 2021. https://doi.org/10.1002/osp4.495 |
||||
| , Article | ||||
| , Belgium, Switzerland | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/34123394 | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Obesity | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
| Office-based Approach to Urinary Tract Infections in 50 000 Patients: Results From the REWIND Study | ||||
| Cai T, Palagin I, Brunelli R, Cipelli R, Pellini E, Truzzi JC, Van Bruwaene S | ||||
| Cai T: Department of Urology, Santa Chiara Regional Hospital, Trento, Italy. Cipelli: Obs Studies Consultat, IQVIA, RWS, Milan, Italy. | ||||
| , Article | ||||
| , Belgium, Brazil, Italy, Russian Federation | ||||
| Abstract: https://www.sciencedirect.com/science/article/pii/S0924857920301230?via%3Dihub | ||||
| Condition | Year | Language | Analysis type | |
| , Miscellaneous | 2021 | English | , clinical setting: Secondary care, Epidemiological study, Retrospective database analysis | |
| Incorporating patient generated health data into pharmacoepidemiological research. Pharmacoepidemiology and Drug Safety. | ||||
| Alison Bourke 1, William G Dixon 2, Andrew Roddam 3, Kueiyu Joshua Lin 4, Gillian C Hall 5, Jeffrey R Curtis 6, Sabine N van der Veer 7, Montse Soriano-Gabarró 8, Juliane K Mills 9, Jacqueline M Major 10, Thomas Verstraeten 11, Matthew J Francis 12, Dorothee B Bartels 13 | ||||
| 1Real World Solutions, IQVIA, London, UK. 2Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK. 3Data & Computational Sciences, GSK, London, UK. 4Brigham and Women's & Department of Medicine, Boston, Massachusetts, USA. 5Gillian Hall Epidemiology Ltd, London, UK. 6Division of Clinical Immunology & Rheumatology, The University of Birmingham, Birmingham, Alabama, USA. 7Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. 8Bayer AG, Berlin, Germany. 9PRA Health Sciences, Raleigh, North Carolina, USA. 10Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. 11P95 Pharmacovigilance and Epidemiology, Leuven, Belgium. 12The Procter & Gamble Company, Cincinnati, Ohio, USA. 13UCB Pharma, Anderlecht, Belgium. | ||||
| Pharmacoepidemiol Drug Saf . 2020 Dec;29(12):1540-1549. doi: 10.1002/pds.5169. Epub 2020 Nov 13. |
||||
| , Article | ||||
| , Belgium, Germany, UK, USA | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/33146896/ | ||||
| Condition | Year | Language | Analysis type | |
| , Database Validity and methodology, Health status & patient reported outcomes, Patient Registries & Real-World Study Methods | 2021 | English | , Patient questionnaire, Review | |
| The prevalence of polypharmacy and the use of potentially inappropriate medications (PIMs): a cross-national study in five European countries - Preliminary Results | ||||
| Bennie M1, Elseviers M2, Schubert I3, Poluzzi E4, MacBride S5, Sermet C6, Jouaville Abrouk LS7, Menon S7, Trehony J7, Nasuti P7, Taxis K8 | ||||
| 1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde / Information Services Division, NHS National Services Scotland, UK 2 Clinical Pharmacology, Ghent University, Belgium Centre for Innovation and Care, University of Antwerp, Belgium 3 PMV Research Group, Faculty of Medicine and University Hospital of Cologne, University for Cologne, Germany 4 University of Bologna, Italy 5 NHS Greater Glasgow and Clyde, Scotland 6 IRDES, Institut de Recherche en Economie de la Santé, France 7 IQVIA Real World Solutions, London, UK / France 8 University of Groningen, PharmacoTherapy, Epidemiology and Economics, Groningen, The Netherlands | ||||
| European Drug Utilisation Resarch Group (EuroDURG) Conference 2020, Szeged, Hungary, 4-7 March 2020 |
||||
| , Poster | ||||
| , Belgium, France, Germany, Italy, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Clinical practice, Public Health | 2020 | English | , Population Based Study, Public Health, Retrospective database analysis | |
| Predictors of iron‑deficiency anemia in primary care older adults: a real‑world European multi‑country longitudinal study | ||||
| Vetrano DL, Zucchelli A, Marconi E, Levi M, Pegoraro V, Cataldo N, Heiman F, Cricelli C, Lapi F | ||||
| Vetrano DL: Department of Geriatrics, Catholic University of Rome and IRCCS Fondazione Policlinico “A. Gemelli”, Rome, Italy. Pegoraro V: Medical Writer & HEOR Consultat, IQVIA, RWS, Milan, Italy. Heiman F: HEOR Engagement Manager, IQVIA, RWS, Milan, Italy | ||||
| Aging Clin Exp Res (2020). https://doi.org/10.1007/s40520-019-01454-6 |
||||
| , Article | ||||
| , Belgium, Germany, Italy, Spain | ||||
| Abstract: https://link.springer.com/article/10.1007/s40520-019-01454-6 | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2020 | English | , Epidemiological study, Retrospective database analysis | |
| External Validation of the Core Obesity Model to Assess the Cost Effectiveness of Weight Management Interventions | ||||
| Sandra Lopes 1, Pierre Johansen 2, Mark Lamotte 3, Phil McEwan 4, Anamaria-Vera Olivieri 5, Volker Foos 4 | ||||
| 1Novo Nordisk A/S, Søborg, Denmark. snlb@novonordisk.com. 2Novo Nordisk A/S, Søborg, Denmark. 3IQVIA, Zaventem, Belgium. 4Health Economics and Outcomes Research Ltd, Cardiff, UK. 5IQVIA, Basel, Switzerland. | ||||
| Pharmacoeconomics 2020 https://doi.org/10.1007/s40273-020-00941-3 + Pharmacoeconomics. 2021 Jan;39(1):137-138. doi: 10.1007/s40273-020-00982-8. Epub 2020 Nov 30 |
||||
| , Article | ||||
| , Belgium, Denmark, Switzerland, UK | ||||
| Abstract: https://pubmed.ncbi.nlm.nih.gov/32656686/ | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Obesity | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
| GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data. | ||||
| Divino V, Boye KS, Lebrec J, DeKoven M, Norrbacka K | ||||
| IQVIA, Eli Lilly | ||||
| Journal. Diabetes Ther. 2019 Jun;10(3):1067-1088. |
||||
| , Article | ||||
| , Belgium, Canada, France, Germany, Italy, Netherlands | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31028689 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2019 | English | , Retrospective database analysis | |
| Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe | ||||
| Fife D, Waller J, Kaplan S, Hu P, Phillips S, Oliveria SA, Richarz U | ||||
| Fife: Janssen Research and Development, LLC Waller: Adephi Real World Kaplan: Teva Pharmaceutical Indusries Ltd. Hu: Janssen Global Services Phillips: IQVIA Oliveria, IQVIA Richarz: Janssen Research and Development, LLC | ||||
| Clin Drug Investig (2019). https://doi.org/10.1007/s40261-019-00831-3 |
||||
| , Article | ||||
| , Belgium, France, Germany, Spain, UK | ||||
| Abstract: https://link.springer.com/article/10.1007/s40261-019-00831-3 | ||||
| Condition | Year | Language | Analysis type | |
| , Drug safety, Drug Utlization Study | 2019 | English | , Population Based Study, Retrospective database analysis | |
| Gender differences in determinants of iron-deficiency anemia: a population-based study conducted in four European countries | ||||
| Levi M1, Simonetti M2, Marconi E2, Brignoli O3, Cancian M3, Masotti A4, Pegoraro V5, Heiman F5, Cricelli C3, Lapi F2 | ||||
| 1 Local Health Unit Tuscany Centre, Florence, Italy 2 Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy 3 Italian College of General Practitioners and Primary Care, Florence, Italy 4 Department of Transfusion Medicine, Pordenone, Italy 5 IQVIA, Milan, Italy | ||||
| Annals of Hematology (2019) 98:15731582 |
||||
| , Article | ||||
| , Belgium, Germany, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2019 | English | , Database Study, Epidemiological study, Real World Data, Real World Evidence, Retrospective cohort analysis, Retrospective database analysis | |
| Real-world data confirming the efficacy and safety of decitabine in acute myeloid leukaemia - results from a retrospective Belgian registry study. | ||||
| Meers S1, Bailly B2, Vande Broek I3, Malfait B4, Van Hoorenbeeck S4, Geers J4, Braakman J5, Van Kouwenhove M6, Doyle M7, Diels J8, Caekelbergh K9, Chevalier P9, Dierickx D10. | ||||
| 1 Department Oncology, AZ Klina , Brasschaat , Belgium. 2 Department Haematology, Groupe Jolimont , Haine Saint-Paul , Belgium. 3 Department Oncology, AZ Nikolaas , Haematology, Sint Niklaas , Belgium. 4 Department Market Access, Janssen-Cilag NV , Beerse , Belgium. 5 Department Market Access, Janssen-Cilag BV , Breda , The Netherlands. 6 Department Medical, Janssen-Cilag BV , Breda , The Netherlands. 7 Department Medical, Janssen Ireland , Dublin 24 , Ireland. 8 Department Statistics and Modelling, Janssen Pharmaceutica NV , Beerse , Belgium. 9 Department Real-World Solutions, IQVIA , Zaventem , Belgium. 10 Department Haematology, UZ Leuven , Leuven , BelgiumDepartment Haematology. | ||||
| , Abstract | ||||
| , Belgium | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31551014 | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease, Oncology | 2019 | English | , Retrospective database analysis | |
| Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe | ||||
| Kotseva K1, Gerlier L2, Sidelnikov E3, Kutikova L3, Lamotte M2, Amarenco P4, Annemans L5 | ||||
| 1 Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, UK 2 IQVIA, Zaventem, Belgium 3 Amgen (Europe) GmbH, Rotkreuz, Switzerland 4 Department of Neurology and Stroke Centre, Bichat Hospital, Paris, France 5 University of Ghent, Belgium | ||||
| Eur J Prev Cardiol. 2019 Jul;26(11):1150-1157. |
||||
| , Article | ||||
| , Belgium, France, Poland, Portugal, Spain, Switzerland, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30955367 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2019 | English | , Burden of illness, Clinical setting: Primary care, direct to patient research, Observational study | |
| Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. | ||||
| Kotseva K1, Gerlier L2, Sidelnikov E3, Kutikova L3, Lamotte M2, Annemans L4, Amarenco P5 | ||||
| 1 Imperial College London, London, United Kingdom 2 IQVIA, Zaventem, Belgium 3 Amgen Europe GmbH, Zug, Switzerland 4 Ghent University, Ghent, Belgium 5 Hospital Bichat-Claude Bernard, Paris, France | ||||
| European Society of Cardiology (ESC) Congress, 2018, Munich, Germany |
||||
| , Poster | ||||
| , Belgium, France, Poland, Portugal, Spain, Switzerland, UK | ||||
| Abstract: https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-3-Health-economics/176943-patient-and-caregiver-productivity-loss-and-indirect-costs-associated-with-cardiovascular-events-in-europe | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
| TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIES | ||||
| Norrbacka K, Divino V, Boye K, Lebrec J, Dekoven M | ||||
| Eli Lilly, IQVIA | ||||
| ISPOR Europe 2018 |
||||
| , Poster | ||||
| , Belgium, Canada, France, Germany, Italy, Netherlands | ||||
| Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84796?pdfid=57383 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2018 | English | , Retrospective database analysis | |
| Characteristics, resource utilization and safety profile of patients prescribed with neuropathic pain treatments: a real-world evidence study on general practices in Europe. | ||||
| Katz P1, Pegoraro V2, Liedgens H1. | ||||
| 1 Grunenthal GmbH , Aachen , Germany. 2 QuintilesIMS, Milan, Italy. | ||||
| Current Medical Research and Opinion |
||||
| , Article | ||||
| , Belgium, Germany, Italy, Spain, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28537441 | ||||
| Condition | Year | Language | Analysis type | |
| , Pain | 2017 | English | , Database Study, Epidemiological study, Longitudinal study, Observational study, Real World Data, Real World Evidence, Retrospective cohort analysis, Retrospective database analysis | |
| Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model | ||||
| Gerlier L1, Hackett J2, Lawson R2, Dos Santos Mendes S3, Weil-Olivier C4, Schwehm M5, Eichner M6,7 | ||||
| 1 QuintilesIMS, Real-World Evidence Solutions, Zaventem, Belgium 2 AstraZeneca, Gaithersburg, MD, USA 3 AstraZeneca, Brussels, Belgium (Current affiliation: MSD, Brussels, Belgium) 4 Department of Pediatrics, University Paris VII, Paris, France 5 ExploSYS GmbH, Leinfelden-Echterdingen, Germany 6 Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany 7 Epimos GmbH, Dusslingen, Germany | ||||
| JHEOR 2017;5(1):89-108 |
||||
| , Article | ||||
| , Australia, Belgium, Finland, France, Germany, Greece, Italy, Luxembourg, Netherlands, Poland, Portugal, Spain, Sweden, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Immunology and Vaccination, Infectious disease, Respiratory disease | 2017 | English | , Epidemiological study, Public Health | |
| GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. | ||||
| Divino V., DeKoven M., Khan FA., Boye KS., Sapin H., Norrbacka K. | ||||
| Lilly. IMS authors: Divino V, DeKoven M | ||||
| Diabetes Ther. |
||||
| , Article | ||||
| , Belgium, France, Germany, Netherlands, Sweden | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/28070733 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| SCHÉMAS THÉRAPEUTIQUES ET POSOLOGIQUES CHEZ DES PATIENTS AVEC UN DIABÈTE DE TYPE 2 (DT2) INITIANT UN TRAITEMENT PAR AGONISTE DU RÉCEPTEUR DU GLUCAGON-LIKE PEPTIDE 1 (AR GLP-1) EN EUROPE | ||||
| Norrbacka K, Divino V, Dekoven M, Boye KS | ||||
| Eli Lilly, IQVIA | ||||
| Societé Francophone du Diabete 2017 |
||||
| , Poster | ||||
| , Belgium, Canada, France, Germany, Italy, Netherlands | ||||
| Abstract: https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/evenements/17sfd_final_v12.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2017 | English | , Retrospective database analysis | |
| Epidemiology of iron deficiency anaemia in four European countries: a population-based study in primary care. | ||||
| Levi M1-2, Rosselli M3, Simonetti M1, Brignoli O4, Cancian M4, Masotti A5, Pegoraro V6, Cataldo N6, Heiman F6, Chelo M1, Cricelli I1, Cricelli C4, Lapi F1. | ||||
| 1 Health Search Italian College of General Practitioners and Primary Care, Florence 2 Department of Health Sciences, University of Florence, Florence, Italy 3 Institute for Liver and Digestive Health, Royal Free Hospital, University College of London, London, UK 4 Italian College of General Practitioners and Primary Care, Florence 5 Department of Transfusion Medicine, Local Health Authority n°5, Pordenone 6 IMS Health Information Solutions Medical Research srl, Milan, Italy | ||||
| Eur J Haematol. 2016 May 7. doi: 10.1111/ejh.12776 |
||||
| , Article | ||||
| , Belgium, Germany, Italy, Spain | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=Epidemiology+of+iron+deficiency+anaemia+in+four+European+countries%3A+a+population-based+study+in+primary+care. | ||||
| Condition | Year | Language | Analysis type | |
| , Nutritional Disorders | 2016 | English | , Database Study, Epidemiological study, Longitudinal study, Real World Data, Real World Evidence, Retrospective database analysis | |
| Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature. | ||||
| Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1. | ||||
| 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden. | ||||
| Clinical Epidemiology |
||||
| , Article | ||||
| , Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pmc/articles/PMC4887072/ | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | , Literature Review | |
| Characteristics, resources utilization and safety profile of patients with acute pain: a European real world evidence study. | ||||
| Katz P1, Pegoraro V2, Heiman F, Liedgens H1. | ||||
| 1 Grunenthal GmbH, Aachen, Germany 2 IMS Health Information Solutions Italy Srl, Milan, Italy. | ||||
| ISPOR 19th Annual European Congress, 2016, 29 October-2 November, Vienna, Austria. |
||||
| , Poster | ||||
| , Belgium, Germany, Italy, Spain, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease, Neurological disorders, Pain | 2016 | Italian | , Clinical setting: Primary care, Database Study, Epidemiological study, Longitudinal study, Real World Data, Real World Evidence, Retrospective database analysis | |
| Short and long term costs associated with different cardiovascular events in Belgium. | ||||
| Caekelbergh K1, Chevalier P1, Lamotte M1, Kutikova L2, Schutyser E3, Annemans L4 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Amgen (Europe) GmbH, Zug, Switzerland 3 nv Amgen sa, Brussels, Belgium, 4 Ghent University - Brussels University, Ghent, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Miscellaneous | 2016 | English | , Cost of illness | |
| Hospitalization cost and length of stay associated with HPV-related diseases | ||||
| Tsakeu E1, Petit C2, Chevalier P1 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Sanofi-Pasteur MSD, Diegem, Belgium | ||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| 2016 | English | |||
| Hospitalization cost and length of stay associated with HPV-related diseases | ||||
| Tsakeu E1, Petit C2, Chevalier P1 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Sanofi-Pasteur MSD, Diegem, Belgium | ||||
| , Abstract, Abstract | ||||
| , Belgium, Belgium | ||||
| Condition | Year | Language | Analysis type | |
| 2016 | English | |||
| Hospitalization cost and length of stay associated with HPV-related diseases. | ||||
| Tsakeu E1, Petit C2, Chevalier P1 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Sanofi-Pasteur MSD, Diegem, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | , Cost analysis | |
| Hospitalization costs associated with Crohn's disease and ulcerative colitis in Belgium. | ||||
| Chevalier P, Lamotte M | ||||
| QuintilesIMS, Zaventem, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Miscellaneous | 2016 | English | , Cost of illness | |
| Epidemiology of patients receiving hematopoietic stem cell patients in Belgium. | ||||
| Chevalier P, Tsakeu E, Lamotte M | ||||
| QuintilesIMS, Zaventem, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2016 | English | ||
| Description of first-line treatments in patients with non-resectable colorectal cancers in Belgium. | ||||
| Chevalier P, van Gils C, Lamotte M | ||||
| QuintilesIMS, Zaventem, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | ||
| In-hospital mortality and complications following surgical resection of glioblastoma. | ||||
| Chevalier P, van Gils C, Lamotte M | ||||
| QuintilesIMS, Zaventem, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2016 | English | ||
| Three-monthly long-acting formulation of paliperidone palmitate is a dominant treatment option, cost saving while adding QALYs, compared to the one-monthly formulation in the treatment of schizophrenia in Belgium: a cost-utility study. | ||||
| De Moor R1, Malfait B2, Tedouri F3, De Vos C2, Van Gils C1 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Janssen-Cilag NV, Beerse, Belgium 3 Janssen Pharmaceutica NV, Beerse, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Mental health | 2016 | English | ||
| Rationale and design of a multi-center survey to evaluate productivity losses and indirect costs after cardiovascular events in Europe. | ||||
| Gerlier L1, Sidelnikov E2, Kutikova L2, Lamotte M1, Annemans L3 | ||||
| 1 QuintilesIMS, Zaventem, Belgium 2 Amgen (Europe) GmbH, Zug, Switzerland 3 University of Ghent, Ghent, Belgium | ||||
| 19th ISPOR Annual European Congress, 2016, October 29- November 2, Vienna, Austria |
||||
| , Abstract | ||||
| , Belgium, Czech, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Switzerland, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2016 | English | ||
| Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. | ||||
| Peyrin-Biroulet L1, Van Assche G2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. | ||||
| 1Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. 2Division of Gastroenterology, University Hospitals Leuven, Leuven Belgium. 3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany. 4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom. 6Gastroenterology Practice, Minden, Germany. 7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece. 8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. 9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom. 10IMS Health, Real World Evidence Solutions, Spain. 11Merck & Co., Inc., Kenilworth, NJ, United States | ||||
| Dig Liver Dis. 2016 Jun;48(6):601-7. |
||||
| , Article | ||||
| , Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2016 | English | , Burden of illness, Patient questionnaire, Survey research | |
| Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study | ||||
| Van Assche G1, Peyrin-Biroulet L2, Sturm A3, Gisbert JP4, Gaya DR5, Bokemeyer B6, Mantzaris GJ7, Armuzzi A8, Sebastian S9, Lara N10, Lynam M10, Rojas-Farreras S10, Fan T11, Ding Q11, Black CM11, Kachroo S11. | ||||
| 1Division of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. Electronic address: gert.vanassche@uzleuven.be. 2Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. 3Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany. 4Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica and Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 5Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK. 6Gastroenterology Practice, Minden, Germany. 7Department of Gastroenterology, Evangelismos Hospital, Athens, Greece. 8IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. 9Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK. 10IMS Health, Real World Evidence Solutions, Barcelona, Spain. 11Merck & Co., Inc., Rahway, NJ, United States. | ||||
| Dig Liver Dis. 2016 Jun;48(6):592-600 |
||||
| , Article | ||||
| , Belgium, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2016 | English | , Burden of illness, Patient questionnaire | |
| THREE-MONTHLY LONG-ACTING ANTIPSYCHOTIC THERAPY RESULTS IN A BETTER TREATMENT CONTINUITY COMPARED TO A ONE-MONTHLY OR BI-WEEKLY TREATMENT IN SCHIZOPHRENIA | ||||
| Tedouri F1, Denee TR2, Malfait B3, Van Impe K2 | ||||
| 1Janssen Pharmaceutica NV, Beerse, Belgium, 2Janssen-Cilag BV, Tilburg, The Netherlands, 3Janssen-Cilag NV, Beerse, Belgium | ||||
| ISPOR 19th Annual European Congress Vienna, Austria October, 2016 |
||||
| , Poster | ||||
| , Belgium, Netherlands | ||||
| Condition | Year | Language | Analysis type | |
| , Mental health | 2016 | English | , Retrospective database analysis | |
| Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. | ||||
| Gerlier L, Lamotte M, Dos Santos Mendes S, Damm O, Schwehm M, Eichner M. | ||||
| Paediatr Drugs., 2016, Aug, 18(4):303-18 |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/27272706 | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease | 2016 | English | ||
| Treatment and dosing patterns among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Europe. | ||||
| Kirsi Norrbacka; Victoria Divino; Mitch DeKoven; Kristina Secnik Boye | ||||
| Lilly. IMS authors: Divino V, DeKoven M | ||||
| European Association for the Study of Diabetes 52nd annual meeting |
||||
| , Poster | ||||
| , Belgium, France, Germany, Netherlands, Sweden | ||||
| Abstract: https://www.easd.org/virtualmeeting/home.html#!resources/treatment-and-dosing-patterns-among-patients-with-type-2-diabetes-initiating-glucagon-like-peptide-1-receptor-agonists-glp-1-ras-in-europe-5ef3fe71-7e5d-4bdd-8b32-b4187d2a9aac | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2016 | English | , Retrospective database analysis | |
| AN EPIDEMIOLOGICAL EVALUATION OF THE INCIDENCE OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN PATIENTS WITH HIP OR KNEE REPLACEMENT SURGERY AND OF ITS IMPACT ON THE AVERAGE LENGTH OF STAY AND HOSPITALIZATION COST | ||||
| Chevalier P, Lamotte M | ||||
| IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2015 | English | ||
| THE ECONOMIC BURDEN OF POOR ADHERENCE TO STATINS IN BELGIUM | ||||
| Ramos M, Caekelbergh K, Lamotte M | ||||
| IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2015 | English | , Burden of illness, Cost analysis | |
| ASSESSING THE COST-EFFECTIVENESS OF USING ACLIDINIUM BROMIDE 400 µG /FORMOTEROL FUMARATE DIHYDRATE 12 µG COMPARED TO ACLIDINIUM BROMIDE 400 µG IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ||||
| Ramos M1, Haughney J2, Henry N3, Lindner L4, Lamotte M1 | ||||
| 1IMS Health, Vilvoorde, Belgium, 2University of Aberdeen, Aberdeen, UK, 3IMS Health, London, UK, 4AstraZeneca, Barcelona, Spain | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium, Spain, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2015 | English | , Cost analysis | |
| AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF PERCUTANEOUS CORONARY INTERVENTIONS ON THE HOSPITALIZATION COST, LENGTH OF STAY AND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROMES | ||||
| Chevalier P, Lamotte M | ||||
| IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2015 | English | ||
| THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS IN BELGIUM: PRESCRIBING BEHAVIOR AND MISUSE OF ANTIDEPRESSANTS | ||||
| Ramos M1, Brouyère S2, Caekelbergh K1, Lamotte M1 | ||||
| 1IMS Health, Vilvoorde, Belgium, 2IMS Health, Drogenbos, Belgium | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Mental health | 2015 | English | ||
| THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIDEPRESSANTS IN BELGIUM | ||||
| Caekelbergh K, Ramos M, Lamotte M | ||||
| IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Mental health | 2015 | English | ||
| THE ECONOMIC CONSEQUENCES OF THE USE OF ANTIBIOTICS IN BELGIUM | ||||
| Caekelbergh K, Ramos M, Lamotte M | ||||
| IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| 2015 | English | |||
| AVOIDABLE HOSPITALIZATIONS DUE TO MEDICATION ERRORS IN BELGIUM | ||||
| Ramos M, Caekelbergh K, Lamotte M | ||||
| IMS Health, Vilvoorde, Belgium | ||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| 2015 | English | |||
| PUBLIC HEALTH OUTCOMES OF PAEDIATRIC INFLUENZA VACCINATION WITH AN INTRANASAL TETRAVALENT LIVE ATTENUATED VACCINE IN BELGIUM USING A DYNAMIC TRANSMISSION MODEL | ||||
| Gerlier L1, Lamotte M1, Dos Santos Mendes S2, Schwehm M3, Eichner M4 | ||||
| 1IMS Health, Vilvoorde, Belgium, 2AstraZeneca Belux, Uccle, Belgium, 3ExploSYS GmbH, Leinfelden-Echterdingen, Germany, 4Epimos GmbH, Dusslingen, Germany | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| 2015 | English | |||
| ASSESSING THE BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS IN BELGIUM USING A LONGITUDINAL HOSPITAL DATABASE | ||||
| Gerlier L, Lamotte M, Chevalier P | ||||
| IMS Health, Vilvoorde, Belgium | ||||
| ISPOR 18th Annual European Congress Milan, Italy November, 2015 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| 2015 | English | |||
| Cost and co-morbidities associated with hypoglycemic inpatients in Belgium. | ||||
| Chevalier P1, Vandebrouck T2, De Keyzer D2, Mertens A3, Lamotte M1 | ||||
| 1. IMS Health HEOR, Vilvoorde, Belgium 2. Novo Nordisk, Brussels, Belgium 3. University Hospitals of Leuven, Leuven, Belgium | ||||
| The Journal of Medical Economics, Volume 19, 2016 - Issue 1 |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: http://dx.doi.org/10.3111/13696998.2015.1086775 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2015 | English | ||
| In-hospital costs associated with chronic constipation in Belgium: a retrospective database study. | ||||
| Chevalier P, Lamotte M, Joseph A, Dubois D, Boeckxstaens G | ||||
| Health Economics and Outcome Research, IMS Health HEOR, Vilvoorde, Belgium. | ||||
| Neurogastroenterol Motil., 2014, Mar, 26(3):368-376 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2014 | English | , Database Study | |
| Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Belgium. | ||||
| Lamotte M1, Wyffels V2, Knudsen M3, Troelsgaard A4, Hemels M4 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 Janssen, Belgium 3 IMS Health, London, UK 4 Janssen A/S, Denmark | ||||
| ISPOR 19th Annual International Meeting, Montreal, QC, Canada, 31 May–4 June, 2014 |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Economic evaluation | |
| Cost of a pulmonary arterial hypertension-related hospitalization in Belgium | ||||
| Chevalier P1, De Beule J2, Lamotte M1, Hunsche E2, Regulier E2 | ||||
| 1IMS Health, Vilvoorde,Belgium, 2Actelion Pharmaceuticals Ltd., Allschwil, Switzerland | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2014 | English | , Retrospective database analysis | |
| Impact of a pharmacological cardioversion with vernakalant on the management cost of recent atrial fibrillation in Belgium. | ||||
| Lamotte M1, Gerlier L1, Caekelbergh K1, Polifka J2, Lalji K2, Lee E2 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 Cardiome, Vancouver, Canada | ||||
| ISPOR 17th Annual European Congress, 8-12 November, Amsterdam, The Netherlands |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2014 | English | , Budget impact, Cost minimization | |
| treatment continuation and treatment characteristics of 3 long acting antipsychotic medications (paliperidone palmitate, risperidone microspheres and haloperidol decanoate) in Belgium | ||||
| Sermon J1, Geerts P1, Decuypere F2, Weglewski T2, Rijntjes R3, De Hert M4 | ||||
| Janssen-Cilag NV, Beerse, Belgium, 2IMS Health, Vilvoorde, Belgium, 3Janssen-Cilag BV, Tilburg, The Netherlands, 4Katholieke Universiteit Leuven, Kortenberg, Belgium | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Mental health | 2014 | English | , Compliance | |
| Cost of a pulmonary arterial hypertension-related hospitalization in Belgium | ||||
| Chevalier P1, De Beule J2, Lamotte M1, Hunsche E2, Regulier E2 | ||||
| 1IMS Health, Vilvoorde,Belgium, 2Actelion Pharmaceuticals Ltd., Allschwil, Switzerland | ||||
| ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Rheumatology | 2014 | English | , Cost analysis | |
| Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries. | ||||
| Divino V., DeKoven M., Hallinan S., Varol N., Wirta SB., Lee WC., Reaney M. | ||||
| Lilly. IMS authors: Divino V, DeKoven M | ||||
| Diabetes Ther. |
||||
| , Article | ||||
| , Belgium, France, Germany, Netherlands, Sweden, UK | ||||
| Abstract: https://www.ncbi.nlm.nih.gov/pubmed/25366334 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2014 | English | , Retrospective database analysis | |
| Herpes Zoster-Related Health Care Resource Utilization in Cancer Patients in 5 European Countries | ||||
| Gebremeskel B.G.1, Lopez-Gonzalez L.2, Patwardhan P.3, Chin J.4, Schwalm M.S.4, Acosta C.J.3,Margolis J.M.5 | ||||
| VALUE IN HEALTH 17 ; A684 |
||||
| , Abstract | ||||
| , Belgium, France, Germany, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics, Immunology and Vaccination, Oncology | 2014 | English | , Cost of illness, Retrospective database analysis | |
| Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium. | ||||
| Chevalier P1, Lamotte M1, Van Campenhout H2, Eyckerman R2, Annemans L3 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 Pfizer, Brussels, Belgium 3 I-CHER, Ghent University, Brussels University (VUB), Ghent, Belgium | ||||
| J Med Econ., 2013,16(5): 596-605 |
||||
| , Article, Manuscript in preparation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Pain | 2013 | English | , Cost effectiveness | |
| The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. | ||||
| Body JJ1, Chevalier P2, Gunther O3, Hechmati G4, Lamotte M2 | ||||
| 1 CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium 2 IMS Health, Vilvoorde, Belgium 3 Centre for Observational Research, Amgen Ltd, Uxbridge, UK 4 Health Economics, Amgen (Europe) GmbH, Zug, Switzerland | ||||
| J Med Econ., 2013, 16(4): 539-46 |
||||
| , Article, Manuscript in preparation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Musculoskeletal disease, Oncology | 2013 | English | , Burden of illness | |
| The burden of hospitalizations due to hypoglycemia in Belgium. | ||||
| Lamotte M1, Chevalier P1, Vandebrouck T2 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 NovoNordisk, Brussels, Belgium | ||||
| American Diabetes Association (ADA) 73rd Scientific Sessions, 2013, June 21-25, Chicago, IL, USA |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Burden of illness | |
| Estimating the cost of hospitalization for hypoglycemia in Belgium. | ||||
| Lamotte M1, Chevalier P1, Vandebrouck T2 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 NovoNordisk, Brussels, Belgium | ||||
| ISPOR 18th Annual International Meeting, 2013, May 18-22, New Orleans, LA, USA |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2013 | English | , Cost analysis | |
| Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting | ||||
| Kleintjens J1, Li X1, Simoens S2, Thijs V3, Goethals M4, Rietzschel ER5, Asukai Y6, Saka O1, Evers T7, Faes P8, Vansieleghem S8, De Ruyck M8 | ||||
| 1Deloitte Health Economics and Outcomes Research Group, Brussels, Belgium, 2Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 3Department of Neurology, University Hospitals Leuven, Leuven,Belgium, 4Mariaziekenhuis Noord-Limburg, Overpelt, Belgium, 5Department of Public Health, Faculty of Medicine and Health Sciences, Ghent University and Ghent University Hospital, Ghent, Belgium, 6IMS Health, London, UK, 7Global Market Access/HEOR, Bayer HealthCare, Wuppertal, Germany, 8Market Access Department, Bayer HealthCare, J.E. Mommaertslaan 14, 1831 Diegem (Machelen), Belgium | ||||
| PharmacoEconomics DOI 10.1007/s40273-013-0087-9 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2013 | English | , Cost effectiveness | |
| The current management and costs of irritable bowel syndrome with constipation in Belgium: a 2-round expert survey. | ||||
| Caekelbergh K1, Gerlier L, Lamotte M1, Kinoo D2, Meurgey F3, Berdeaux G1 | ||||
| 1 IMS Health HEOR, Vilvoorde, Belgium 2 Almirall, Vilvoorde, Belgium 3 Oukelos sprl, Brussels, Belgium | ||||
| 16th ISPOR Annual European Congress, 2013, November 2-6, Dublin, Ireland |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2013 | English | , Cost of illness | |
| The Economic Burden of Dialysis Patients in Belgium: a Comparison Between Haemo and Peritoneal Dialysis. | ||||
| Dratwa M1, Bogaert AM2, Bouman K3, Warling X4, Hombrouckx R5, Schurgers M6, Dupont P7, Vereerstraeten A8, Van Roost G9, Caekelbergh K10, Lamotte M10, Laplante S11 | ||||
| 1 CHU Brugmann, Brussels, Belgium 2 AZ Sint Elisabeth, Zottegem, Belgium 3 ZNA, Middelheim, Antwerp, Belgium 4 Centre Hospital Régionale Citadelle, Liège, Belgium 5 AZ Zusters van Barmhartigheid, Ronse, Belgium 6 AZ St. Jan, Brugge, Belgium 7 CHU Tivoli, La Louvière, Belgium 8 CHU André Vésale, Montigny-Le-Tilleul, Belgium 9 St. Jan Hospital Brussels, Brussels, Belgium 10 IMS Health, Brussels, Belgium 11 Baxter Healthcare Corporation | ||||
| Outcomes Assessment in End - Stage Kidney Disease Measurements and Applications in Clinical Practice, 2013, 15 : 208-222 |
||||
| , Book chapter | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Nephrology | 2013 | English | , Cost of illness | |
| In-hospital costs associated with chronic constipation in Belgium: a retrospective database study. | ||||
| Chevalier P1, Lamotte M1, Joseph A2, Dubois D3, Boeckxstaens G4 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 Shire, Nyon, Switzerland 3 Université Libre de Bruxelles, Brussels, Belgium 4 University Hospital of Leuven, Leuven, Belgium | ||||
| Neurogastroenterology and Motility (2013) doi: 10.1111/nmo.12269. |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=In-hospital+costs+associated+with+chronic+constipation+in+Belgium%3A+a+retrospective+database+study. | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2013 | English | , Retrospective database analysis | |
| Cost analysis: treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries | ||||
| Duran A1, Spaepen E2,Lamotte M3, Walter E4, Umuhire D5, Lucioni C6, Pinheir B7, Brosa M8, Pujol LKB9, Van Belle S10, Annemans L11 | ||||
| 1 IMS Health, London, UK 2 SBD Analytics BVBA/SPRL, Bekkevoort, Belgium 3 IMS Health, Vilvoorde, Belgium 4 Institute for Pharmaeconomic Research, Health Economics, Vienna, Austria 5 IMS Health, Paris, France 6 Wolters Kluwer Health Italy, Milan, Italy 7 CISEP, Research Centre on the Portuguese Economy, Lisbon, Portugal 8 Oblikue Consulting, Barcelona, Spain 9 Amgen (Europe) GmbH, Zug, Switzerland 10 Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium 11 I-CHER, Ghent University, Brussels University (VUB), Ghent, Belgium | ||||
| Journal of Medical Economics Vol. 15, No. 3, 2012, 1–10 |
||||
| , Article | ||||
| , Austria, Belgium, France, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2012 | English | , Cost analysis | |
| Non-interventional study on the burden of illness in diabetic macular edema (DME) in Belgium. | ||||
| Nivelle E1, Caekelbergh K1, Moeremans K1, Gerlier L1, Drieskens S2, Van Dijck P3 | ||||
| 1 IMS Health HEOR, Vilvoorde, Belgium 2 Panacea Officinalis, Antwerp, Belgium 3 Novartis Pharma, Vilvoorde, Belgium | ||||
| 15th ISPOR Annual European Congress, 2012, November 3-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Cost of illness | |
| Assessing the budget impact of using ScanBag® in CT in 6 European countries. | ||||
| Nivelle E1, Mathou F2, Lamotte M1 | ||||
| 1 IMS Health, Vilvoorde, Belgium 2 Guerbet SA, Villepinte, France | ||||
| 15th ISPOR Annual European Congress, 2012, November 3-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium, France, Germany, Italy, Spain, UK | ||||
| Condition | Year | Language | Analysis type | |
| , Miscellaneous | 2012 | English | , Budget impact | |
| Cost-effectiveness of ticagrelor in the management of acute coronary syndromes in Belgium. | ||||
| Chevalier P1, Lamotte M1, Petit C2 | ||||
| 1 IMS HEOR, Vilvoorde, Belgium 2 Astra Zeneca Belgium, Brussels, Belgium | ||||
| 15th ISPOR Annual European Congress, 2012, November 3-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2012 | English | , Cost effectiveness | |
| The burden of diabetes mellitus in Belgium: a retrospective database study. | ||||
| Lamotte M1, Chevalier P1, Gerlier L1 | ||||
| 1 IMS Health, Vilvoorde, Belgium | ||||
| 15th ISPOR Annual European Congress, 2012, November 3-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2012 | English | , Retrospective database analysis | |
| Cost-Effectiveness Of Tapentadol For Severe Chronic Non-Cancer Pain In Belgium | ||||
| Obradovic M1, Ikenberg R2, Hertel N3, Liedgens H1 | ||||
| 1Grünenthal GmbH, Aachen, Germany, 2IMS Health, Munich, Germany, 3IMS Health, London, UK | ||||
| ISPOR 15th Annual European Congress, 3-7 November 2012, Berlin, Germany |
||||
| , Poster | ||||
| , Belgium | ||||
| Abstract: http://www.ispor.org/congresses/Berlin1112/Posters3.aspx#top | ||||
| Condition | Year | Language | Analysis type | |
| , Pain | 2012 | English | , Cost effectiveness | |
| The cost of diabetes complications in Belgium. | ||||
| Lamotte M1, Chevalier P1 | ||||
| 1 IMS Health, Vilvoorde, Belgium | ||||
| 15th ISPOR Annual European Congress, 2012, November 3-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Diabetes | 2012 | English | , Cost consequence, Cost of illness | |
| Patient adherence to Cosopt® formulations and implications for artificial tear usage | ||||
| Tack F1, Porrez L2,Lamotte M3,Berdeaux G3 | ||||
| 1 MSD, Belgium 2 IMS Health, Belgium 3 IMS HEOR, Belgium | ||||
| Congress of the Academia Ophthalmologica Belgica - OB 2012, 28 - 30 November 2012 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Retrospective database analysis | |
| Impact of a switch to preservative free Dorzolamide-Timolol on ocular surface disease symptoms | ||||
| Stalmans I1, Boons S1, Vandewalle E1, Berdeaux G2, Caekelbergh K2, Gerlier L2 | ||||
| 1 University Hospital, Leuven, Belgium 2 IMS HEOR, Belgium | ||||
| Congress of the Academia Ophthalmologica Belgica - OB 2012, 28 - 30 November 2012 |
||||
| , Poster | ||||
| , Belgium | ||||
| Abstract: http://www.ophthalmologia.be/plugins/events/show_schedule.php?ev_id=31 | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2012 | English | , Prospective study | |
| Evaluation of real-life use of sugammadex for decurarization of neuromuscular blockade in surgical interventions in Belgium. | ||||
| Caekelbergh K1, Lamotte M1 | ||||
| 1 IMS Health, Vilvoorde, Belgium | ||||
| 15th ISPOR Annual European Congress, 2012, November 4-7, Berlin, Germany |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Miscellaneous, Surgery | 2012 | English | , Market impact, Observational study, Survey research | |
| Resource use and cost of hepatitis C related care in Belgium. | ||||
| Nevens F1, Colle I2, Michielsen P3, Robaeys G4, Moreno C5, Caekelbergh K6, Lamotte M6, Wyffels V7 | ||||
| 1 University Hospital Gasthuisberg, Leuven Belgium, 2 Ghent University Hospital, Ghent, Belgium, 3 Antwerp University Hospital, Antwerp, Belgium, 4 ZOL, Genk, Belgium, 5 Erasme Hospital, Brussels, Belgium, 6 IMS Health, Vilvoorde, Belgium, 7 Janssen-Cilag NV, Beerse, Belgium | ||||
| Belgian Week of Gastroenterology, 2012, February 9-11, Ostend, Belgium |
||||
| , Article, Oral presentation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease | 2012 | English | , Cost of illness | |
| Severe hypertriglyceridaemia in patients treated with lipid-modifying agents. | ||||
| Désaméricq G1, Van Ganse E1, Schwalm MS2, Bourke A3, Moulin P4. | ||||
| 1Unité de pharmaco-épidémiologie, faculté d’odontologie UCBL, CHU de Lyon, 69372 Lyon, France 2Cegedim Strategic Data, 92100 Boulogne-Billancourt, France 3The Health Improvement Network, SW8 3QJ London, UK 4Université de Lyon, 69003 Lyon, France Inserm, U870, IFR62, 69008 Lyon, France Inra, UMR1235, 69008 Lyon, France INSA-Lyon, RMND, 69621 Villeurbanne, France Hospices Civils de Lyon, 69008 Lyon, France | ||||
| Diabetes & Metabolism Volume 38, n° 3 pages 277-279 (juin 2012) |
||||
| , Article | ||||
| , Belgium, France, Germany, Italy, UK | ||||
| Abstract: http://www.em-consulte.com/en/article/735594 | ||||
| Condition | Year | Language | Analysis type | |
| , Endocrinology, Metabolic Disorders , Vascular disease | 2012 | English | , Retrospective database analysis | |
| Cost-utility analysis of ranibizumab (Lucentis®) in wet-AMD based on real-life data collected in the HELIOS study after ranibizumab reimbursement in Belgium. | ||||
| Moeremans K1, Gerlier L1, Drieskens S2, Annemans L3, Brié H4, Deruyck M4, Faes P4, Vancayzeele S4 | ||||
| 1 IMS Health Consulting, Vilvoorde, Belgium 2 Panacea Officinalis BVBA, Brussels, Belgium 3 Ghent University - Brussels University, Ghent, Belgium 4 Novartis Pharma AG, Vilvoorde, Belgium | ||||
| ISPOR 16th Annual International Meeting, May 21-25 2011, Baltimore, USA |
||||
| , Poster | ||||
| , Belgium | ||||
| Abstract: http://www.ispor.org/meetings/baltimore0511/Posters1.aspx | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2011 | English | , Cost utility | |
| Cost Analysis of Anaemia Treatment With Erythropoiesis-Stimulating Agents in Cancer Patients Receiving Chemotherapy | ||||
| Duran A1, Spaepen E2, Lamotte M3, Walter E4, Kutikova L5, Pujol B5, Ribnicsek E6, Annemans L7 | ||||
| 1IMS Health, London, UK; 2SBD Analytics BVBA/SPRL, Belgium; 3IMS Health, Vilvoorde, Belgium; 4Institut für Pharmaökonomische Forschung, Vienna, Austria; 5Amgen (Europe) GmbH, Zug, Switzerland; 6Amgen, Vienna, Austria; 7I-CHER Interuniversity Centre for Health Economics Research, UGent, VUB, Belgium | ||||
| 16th Congress of the European Association of Hospital Pharmacists, 30 March - 1 April 2011. |
||||
| , Poster | ||||
| , Austria, Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2011 | English | , Cost analysis | |
| The incidence and outcome of febrile neutropenia in different chemotherapy regimens for cancer patients in Belgium. | ||||
| Chevalier P1, Lamotte M1, Malfait M2, Marciniak A3 | ||||
| 1 IMS Health HEOR, Vilvoorde, Belgium 2 Amgen sa/nv, Brussels, Belgium 3 Amgen Ltd, Uxbridge, UK | ||||
| 14th ISPOR Annual European Congress, 2011, November 5-8, Madrid, Spain |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2011 | English | ||
| Resource use and cost of hepatitis C related care in Belgium. | ||||
| Caekelbergh K1, Lamotte Mark1, Nevens F2, Colle I3, Michielsen P4, Robaeys G5, Moreno C6, Wyffels V7 | ||||
| 1 IMS consulting group, Vilvoorde, Belgium 2 KULeuven, Leuven, Belgium 3 UZ Ghent, Ghent, Belgium 4 UZ Antwerp, Antwerp, Belgium 5 ZOL Genk, Genk, Belgium 6 ULB, Brussels, Belgium 6 Janssen-Cilag NV, Beerse, Belgium 7 Janssen-Cilag NV, Beerse, Belgium | ||||
| 14th ISPOR Annual European Congress, 2011, November 5-8, Madrid, Spain |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders, Infectious disease | 2011 | English | , Cost analysis | |
| Evaluation of the clinical and economic burden of chronic constipation in Belgium. | ||||
| Leeuwenkamp O1, Chevalier P1, Lamotte M1 | ||||
| 1 IMS Consulting Group, Vilvoorde, Belgium | ||||
| 14th ISPOR Annual European Congress, 2011, November 5-8, Madrid, Spain |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Abstract: http://www.ispor.org/congresses/Spain1111/Posters3.aspx PGI13 | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2011 | English | ||
| Belgian cost-utility analysis of Gilenya® (Fingolimod) in the management of adults with active relapsing remitting multiple sclerosis. | ||||
| Drieskens S1, Moeremans K2 | ||||
| 1 Panacea, Brussels, Belgium 2 IMS Health Consulting, Vilvoorde, Belgium | ||||
| 14th ISPOR Annual European Congress, 2011, November 5-8, Madrid, Spain |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Neurological disorders | 2011 | English | ||
| The incidence and outcome of febrile neutropenia in different chemotherapy regimens for cancer patients in Belgium. | ||||
| Chevalier P1, Lamotte M1, Malfait M2, Marciniak A3 | ||||
| 1 IMS Health HEOR, Brussels, Belgium 2 Amgen nv, Brussels, Belgium 3 Amgen Ltd, Uxbridge, UK | ||||
| The European Multidisciplinary Cancer Congress, 2011, September 23-27, Stockholm |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2011 | English | ||
| An epidemiological evaluation of chemotherapy used in the treatment of metastatic prostate cancer. | ||||
| Chevalier P1, Moeremans K1 | ||||
| 1 IMS Consulting Group, Vilvoorde, Belgium | ||||
| 14th ISPOR Annual European Congress, 2011, November 5-8, Madrid, Spain |
||||
| , Abstract, Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2011 | English | ||
| Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. | ||||
| Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2 | ||||
| 1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium | ||||
| Eur Heart J. 2011 Sep;32(17):2143-52 |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21471134 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. | ||||
| Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F. | ||||
| BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704. |
||||
| , Article | ||||
| , Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/21923932 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2011 | English | , Observational study, Prospective study | |
| Cost of dialysis in Belgium | ||||
| Dratwa M1, Bogaert A2, Caekelbergh K3, Lamotte M3, Laplante S4 | ||||
| 1CHU Brugmann, Brussels, Belgium; 2AZ Zusters van Barmhartigheid, Ronse, Belgium; 3HEOR, IMS Health, Brussels, Belgium; 4Baxter World Trade sprl, Brussels, Belgium | ||||
| XLVII ERA-EDTA Congress, in Munich, Germany, (June 25-28, 2010). |
||||
| , Poster | ||||
| , Belgium | ||||
| Abstract: http://www.abstracts2view.com/era/view.php?nu=ERA10L_471 | ||||
| Condition | Year | Language | Analysis type | |
| , Transplant | 2010 | English | , Cost of illness | |
| Les couts de la dialyse en Belgique | ||||
| Dratwa M1, Bogaert AM2, Bouman K, Caekelbergh K, Lamotte M, Laplante S | ||||
| 1 CHU Brugmann, Bruxelles, Belgium 2 AZ Sint Elisabeth, Ronse, 3N ephrologie, Zna Middelheim, Antwerpen, 4 HEOR-IMS Health, Bruxelles, Belgium 5 Baxter Healthcare Corporation, Bruxelles, Belgique | ||||
| 12ème Réunion commune des Sociétés de Néphrologie et de Dialyse - Bruxelles September 30 2010. |
||||
| , Poster | ||||
| , Belgium | ||||
| Abstract: http://www.rein-eform.org/images/congres/2010/pre_programme.pdf | ||||
| Condition | Year | Language | Analysis type | |
| , Transplant | 2010 | English | , Cost of illness | |
| Quality of life, outcomes and costs in the Belgian population receiving 90Y-Zevalin for non-hodgkin lymphoma: a study for reimbursement revision. | ||||
| Caekelbergh K, Moeremans K | ||||
| IMS Health Consulting, Brussels, Belgium | ||||
| ISPOR 13th Annual European Congress, 2010, November 6-9, Prague, Czech Republic |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2010 | English | , Quality of life | |
| Resource use and costs of patients undergoing dialysis in Belgium. | ||||
| Caekelbergh K1, Lamotte M1, Dratwa M2, Bogaert AM3, Bouman K4, Laplante S5 | ||||
| 1 IMS Health Consulting, Brussels, Belgium 2 CHU Brugmann, Brussels, Belgium 3 AZ St Elisabeth, Zottegem, Belgium 4 ZNA Middelheim, Antwerpen, Belgium 5 Baxter Healthcare Corporation, Braine l'Alleud, Belgium | ||||
| ISPOR 13th Annual European Congress, 2010, November 6-9, Prague, Czech Republic |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Nephrology | 2010 | English | , Cost analysis | |
| An epidemiological evaluation of the incidence of deep venous thrombosis and pulmonary embolism in patients with hip or knee replacement surgery and of its impact on the average length of stay | ||||
| Chevalier P, Lamotte M | ||||
| IMS Health Consulting, Brussels, Belgium | ||||
| ISPOR 13th Annual European Congress, 2010, November 6-9, Prague, Czech Republic |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| 2010 | English | |||
| Patient co-morbidities affect the cost of dialysis patients in Belgium. | ||||
| Laplante S1, Walker DR2, Caekelbergh K3, Lamotte M3, Dratwa M4, Bogaert AM5, Bouman K6 | ||||
| 1 Baxter Healthcare Corporation, Braine l'Alleud, Belgium 2 Baxter Healthcare Corporation, McGaw Park, IL, USA 3 IMS Health Consulting, Brussels, Belgium 4 CHU Brugmann, Brussels, Belgium 5 AZ St Elisabeth, Zottegem, Belgium 6 ZNA Middelheim, Antwerpen, Belgium | ||||
| ISPOR 13th Annual European Congress, 2010, November 6-9, Prague, Czech Republic |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Nephrology | 2010 | English | ||
| The cost utility of autologous chondrocytes implantation using ChondroCelect in symptomatic knee cartilage lesions in Belgium. | ||||
| Gerlier L1, Lamotte M1, Wille M2, Kreuz PC3, Vanlauwe J4, Dubois D5, Meurgey FM6 | ||||
| 1 IMS Health Consulting, Vilvoorde, Belgium 2 TiGenix NV, Leuven, Belgium 3 University Medical Center Rostock, Rostock, Germany 4 University Hospital Pellenberg, Leuven, Belgium 5 Patient Value Solutions, Huldenberg, Belgium 6 Oukelos SPRL, Brussels, Belgium | ||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Musculoskeletal disease | 2010 | English | ||
| Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. | ||||
| Moeremans K1, Hemmett L2, Hjelmgren J3, Allegri G4, Smets E5 | ||||
| 1 IMS Health, Brussels, Belgium 2 Tibotec, Buckinghamshire, UK 3 Janssen-Cilag AB, Stockholm, Sweden 4 Janssen-Cilag SpA, Cologno Monzese, Italy 5 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium | ||||
| Pharmacoeconomics, 2010, 28 (Suppl 1): 147-167 |
||||
| , Article | ||||
| , Belgium, Italy, Nordic, Sweden, UK | ||||
| Condition | Year | Language | Analysis type | |
| , HIV AIDS | 2010 | English | , Cost effectiveness | |
| The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma. | ||||
| Gerlier L1, Lamotte M1, Awada A2, Bosly A3, Bries G4, Cocquyt V5, Focan C6, Henry S7,8, Lalami Y2, Machiels JP9, Mebis J10, Straetmans N11, Verhoeven D12, Somers L13 | ||||
| 1 IMS Health Consulting, Vilvoorde Belgium 2 Jules Bordet Institute, Brussels, Belgium 3 University Hospital of Mont-Godinne, Yvoir, Belgium 4 Virga Jesse Hospital, Hasselt, Belgium 5 University Hospital Ghent, Gent, Belgium 6 CHC-Saint-Joseph Clinic, Liège, Belgium 7 University Hospital of Mont-Godinne, Yvoir, Belgium 8 Sainte-Elisabeth Clinic, Namur, Belgium 9 UCL Saint-Luc University Hospital, Brussels, Belgium 10 Virga Jesse Hospital, Hasselt, Belgium 11 Jolimont Hospital, Haine-Saint-Paul, Belgium 12 AZ Klina, Brasschaat, Belgium 13 OncoLogX, Wuustwezel, Belgium | ||||
| BMC Cancer, 2010, 10:642 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2010 | English | , Survey research | |
| Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. | ||||
| Gschwend MH1, Aagren M2, Valentine WJ1 | ||||
| 1 IMS Health, Basel, Switzerland, 2 Novo Nordisk Inc., New Jersey, United States | ||||
| Journal of Medical Economics, 2009; 12(2): 114–123 |
||||
| , Manuscript in preparation | ||||
| , Belgium, France, Germany, Italy, Spain | ||||
| Abstract: http://informahealthcare.com/doi/abs/10.3111/13696990903080344 | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2009 | English | , Cost effectiveness | |
| The cost-effectiveness of titration to goal with branded rosuvastatin compared to generic simvastatin in patients with elevated low-density lipoprotein cholesterol: primary and secondary prevention in the Belgian health care setting. | ||||
| Van den Steen D1, Petit C2, Lamotte M1 | ||||
| 1 IMS Health Consulting, Brussels, Belgium, 2 AstraZeneca, Brussels, Belgium | ||||
| ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2009 | English | , Cost effectiveness | |
| Cost-utility of autologous chondrocytes implantation using ChondroCelect® in symptomatic knee cartilage defects (Belgium). | ||||
| Gerlier L1, Lamotte M1, Wille M2, Dubois D3, Meurgey F4 | ||||
| 1 IMS Health, Brussels, Belgium 2 TiGenix, Leuven, Belgium 3 Patient Value Solutions, Huldenberg, Belgium 4 Oukelos, Brussels, Belgium | ||||
| ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Musculoskeletal disease | 2009 | English | , Cost utility | |
| Treatment of moderate to severe pain with oxycodone/naloxone to reduce opioid-induced constipation: a cost-utility analysis in Belgium and The Netherlands. | ||||
| Gerlier L1, Lamotte M1, Van Megen Y2 | ||||
| 1 IMS Health, Brussels, Belgium 2 Mundipharma Pharmaceuticals, Hoevelaken, The Netherlands | ||||
| ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France |
||||
| , Poster | ||||
| , Belgium, Netherlands | ||||
| Condition | Year | Language | Analysis type | |
| , Gastrointestinal disorders | 2009 | English | , Cost utility | |
| Management of opioid induced constipation (OIC) in pain patients: a cost of illness study in Belgium and the Netherlands. | ||||
| Caekelbergh K1, Lamotte M1, Van Megen Y2 | ||||
| 1 IMS Health, Brussels, Belgium 2 Mundipharma Pharmaceuticals BV, Hoevelaken, The Netherlands | ||||
| ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France |
||||
| , Poster | ||||
| , Belgium, Netherlands | ||||
| Condition | Year | Language | Analysis type | |
| 2009 | English | , Cost of illness | ||
| The impact of insulin detemir compared to Neutral Protamine Hagedorn insulin on long-term diabetes-related complications: a modeling analysis in type 1 diabetes patients in Belgium, France, Germany, Italy and Spain | ||||
| Gschwend M1, Aagren M2, Valentine WJ1 | ||||
| 1 IMS Health, Basel, Switzerland, 2 Novo Nordisk A/S, Bagsværd, Denmark | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Belgium, France, Germany, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Economic evaluation | |
| Long-term cost-effectiveness of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a basal–bolus regimen in Belgium, France, Germany, Italy and Spain. | ||||
| Gschwend M, Aagren M, Valentine WJ | ||||
| ISPOR 2008 13th Annual International Congress |
||||
| , Poster | ||||
| , Belgium, France, Germany, Italy, Spain | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2008 | English | , Cost effectiveness | |
| Cost-effectiveness of posaconazole (noxafil®) versus standard azole therapy in the prevention of invasive fungal infections among high-risk neutropenic patients in Belgium. | ||||
| Maertens J, Aoun M, Bron D, Jorens P, Peetermans WE, Theunissen K, Engalytcheff A, Van Vlaenderen I, OSullivan AK | ||||
| 10th International Symposium on Febrile Neutropenia, 2008, February 8-9, Brussels, Belgium |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Infectious disease | 2008 | English | , Cost effectiveness | |
| Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. | ||||
| Van Vlaenderen I1, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, Nechelput M, Delabaye I, Gyldmark M, Annemans L1 | ||||
| 1 IMS Health, Brussels, Belgium | ||||
| Acta Clin Belg. 2009 Mar-Apr;64(2):100-12. |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2008 | English | , Cost utility | |
| Epidemiology of idiopathic thrombocytopenic purpura in Belgium assessed using hospital records. | ||||
| Gerlier L1, De Vos C1, Lamotte M1, Malfait M2, Poitrinal P3 | ||||
| 1 IMS Health, Brussels, Belgium 2 Amgen, Brussels, Belgium 3 Amgen, Zug, Switzerland | ||||
| ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2008 | English | , Epidemiological study | |
| Cost effectiveness of darunavir/ritonavir 600/100mg BID in treatment-experienced, LPV/R-naïve, PI-resistent, HIV-infected adults in the United Kingdom, Belgium, Italy and Sweden. | ||||
| Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E | ||||
| ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece |
||||
| , Oral presentation | ||||
| , Belgium, Italy, Sweden, UK | ||||
| Condition | Year | Language | Analysis type | |
| , HIV AIDS | 2008 | English | , Cost effectiveness | |
| Economic burden associated with the management of cervical dysplasia and genital warts in Belgium. | ||||
| Annemans L, Rémy V, Lamure E, Spaepen E, Lamotte M, Muchada JP, Largeron N | ||||
| Journal of Medical Economics, 2008, 11: 135-150 |
||||
| , Manuscript in preparation | ||||
| , Belgium | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/19450115 | ||||
| Condition | Year | Language | Analysis type | |
| , Immunology and Vaccination | 2008 | English | , Burden of illness | |
| Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium. | ||||
| Annemans L, Rémy V, Lamure E, Spaepen E, Lamotte M, Muchada JP, Largeron N | ||||
| Journal of Medical Economics, 2008, 11: 135-150 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2008 | English | , Economic evaluation | |
| Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals. | ||||
| Spaepen E, Demarteau N, Van Belle S, Annemans L | ||||
| The Oncologist, 2008, 13: 596-607 |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: http://theoncologist.alphamedpress.org/cgi/content/full/13/5/596 | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2008 | English | , Cost analysis | |
| Discovery Benelux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia. | ||||
| Herregods MC, Daubresse JC, Michel G, Lamotte M, Vissers E, Vandenhoven G | ||||
| Acta Cardiologica, 2008, 63(4): 493-499 |
||||
| , Article | ||||
| , Belgium, Luxembourg, Luxemburg, Netherlands | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2008 | English | , Economic evaluation | |
| A systematic review of studies on quality of life in animals. | ||||
| Poulsen Nautrup B, Van Vlaenderen I, Poulsen Nautrup C | ||||
| ISPOR 13th Annual International Meeting, 2008, May 3-7, Toronto, Canada |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Animal | 2008 | English | , Review | |
| Long-term cost-benefit ratio of cardiac rehabilitation after percutaneous coronary intervention. | ||||
| Dendale P, Hansen D, Berger J, Lamotte M | ||||
| Acta Cardiologica, 2008, 63: 451-456 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2008 | English | , Cost benefit | |
| Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. | ||||
| Annemans L12, Caekelbergh K2, Roelandts R3, Boonen H4, Leys C5, Nikkels AF6, Van den Haute V7, Van Quickenborne L8, Verhaeghe E9, Leroy B10 | ||||
| 1 University of Ghent, Ghent, Belgium 2 IMS Health, Brussels, Belgium 3 Universitaire Ziekenhuizen, Leuven, Belgium 4 H. Hart, Mol, Belgium 5 ULg University, Liège, Belgium 6 Klinik St Jozef, Saint Vith, Belgium 7 Clinique 2 Alice, Uccle, Belgium 8 A.Z. Sint Lucas, Brugge, Belgium 9 Universitair Ziekenhuis, Ghent, Belgium 10 Cliniques Universitaires St Luc, Brussels, Belgium | ||||
| Eur J Dermatol, 2008, 18(5): 539:546 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Dermatology | 2008 | English | , Cost analysis | |
| A health economic evaluation of the use of erythropoiesis-stimulating agents (ESA) in patients with renal failure treated with haemodialysis. | ||||
| Van Bellinghen LA1, Lamotte M1, Malfait M2 | ||||
| 1 IMS Health, Brussels, Belgium 2 Amgen, Brussels, Belgium | ||||
| ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2008 | English | , Economic evaluation | |
| Health economic consequences related to the diganosis of fibromyalgia syndrome. | ||||
| Annemans L12, Wessely S3, Spaepen E1, Caekelbergh K1, Caubère JP4, Le Lay K5, Taïeb C5 | ||||
| 1 IMS Health, Brussels, Belgium 2 Ghent University, Ghent, Belgium 3 Epidemiology-Psychiatry, London, UK 4 Pierre Fabre, Castres, France 5 Pierre Fabre, Boulogne-Billancourt, France | ||||
| Arthritis and Rheumatism, 2008, 58(3): 895-902 |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: http://www.ncbi.nlm.nih.gov/pubmed/18311794?ordinalpos=18&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | ||||
| Condition | Year | Language | Analysis type | |
| , Neurological disorders | 2008 | English | , Cost analysis | |
| Relief of pain and symptoms in knee cartilage defect is associated with higher SF-36 utility scores: data from a prospective randomized trial of chondrocelect®. | ||||
| Gerlier L1, Lamotte M1, Van Lommel N2, Wille M2, Vanlauwe J3 | ||||
| 1 IMS Health, Brussels, Belgium 2 TiGenix, Leuven, Belgium 3 UZ Pellenberg, Leuven, Belgium | ||||
| ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Orthopedics | 2008 | English | , Utility analysis | |
| Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials. | ||||
| Scheijbeler HW1, Aagren M2, Nielsen S2, Valentine WJ3, Goodall G3, Kotchie RW1 | ||||
| 1 IMS Health, London, UK; 2 Novo Nordisk A/S, Bagsværd, Denmark; 3 IMS Health, Basel, Switzerland. | ||||
| ISPOR 2007 10th Annual European Congress, Dublin, Ireland, 20-23 October 2007 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2007 | English | , Cost effectiveness | |
| Belgian budget impact analyses of aliskiren (tekturna/rasilez) in hypertension. | ||||
| Lecomte P1, Lamotte M2, Esposito G2, Annemans L3, Kotchie RW4, Munk VC5, Vincze G5 | ||||
| 1 Novartis Pharma, Vilvoorde, Belgium 2 IMSHealth, HEOR, Brussels, Belgium 3 Ghent University, Ghent, Belgium 4 IMSHealth, HEOR, London, UK; 5 Novartis Pharma AG, Basel, Switzerland | ||||
| ISPOR 13th Annual International Meeting, Toronto, Ontario, Canada - 3-7 May 2008 |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2007 | English | , Budget impact | |
| Belgian cost-utility analysis of Lucentis (ranibizumab) in wet age-related macular degeneration. | ||||
| Moeremans K, Annemans L, Lecomte P | ||||
| ISPOR 10th Annual European Congress, 2007, October 20-23, Dublin, Ireland |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Ophthalmology | 2007 | English | , Cost utility | |
| Cost of care for HIV/AIDS in Belgium according to disease stage. | ||||
| Caekelbergh K1, Moeremans K1, Annemans L2, De Roo A3, Clumeck N4, Van Wijngaerden E5, Vandercam B6, Moutschen M7, Smets E8 | ||||
| 1 IMS Health, Brussels, Belgium 2 Ghent University, Ghent, Belgium 3 Institute for Tropical Medicine, Antwerp, Belgium 4 St. Pierre University Hospital, Brussels, Belgium 5 University Hospital Leuven, Belgium 6 University Hospital St. Luc, Brussels, Belgium 7 University Hospital Sart Tilman, Liège, Belgium 8 Johnson & Johnson Pharmaceutical Services, Mechelen, Belgium | ||||
| 11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain |
||||
| , Oral presentation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , HIV AIDS | 2007 | English | , Cost of illness | |
| Outcomes and costs of hospital-acquired pneumonia associated with pseudomonas or methicillin-resistant staphylococcus aureus in a sample of Belgian hospitals. | ||||
| Merchant S, Akhras K, Spaepen E, Annemans L | ||||
| ISPOR 10th Annual European Congress, 2007, October 20-23, Dublin, Ireland |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2007 | English | , Burden of illness | |
| Coste-efectividad de la aspirina en la prevención cardiovascular. | ||||
| Lamotte M, Annemans L | ||||
| Med Clin Monogr (Barc), 2007, 7(7): 27-36 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2007 | Spanish | , Cost effectiveness | |
| Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases. | ||||
| Annemans L, Lamotte M, Clarys P, Van den Abeele E | ||||
| Eur J Cardiovasc Prev Rehabil., 2007, 14(6): 815-824 |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?View=Full&ID=22007002690 | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2007 | English | , Economic evaluation | |
| The relative cost-effectiveness of the fentanyl HCL patient-activated transdermal system (ITS) in acute post-operative pain management (POPM) in Greece. | ||||
| Yfantopoulos I, Papanicolaou S, Papagiannopoulou V, Van Bellinghen LA, Annemans L | ||||
| ISPOR 10th Annual European Congress, 2007, October 20-23, Dublin, Ireland ISPOR 2007 10th Annual European Congress |
||||
| , Abstract | ||||
| , Belgium, Greece | ||||
| Condition | Year | Language | Analysis type | |
| , Clinical practice, Health economics | 2007 | English | , Cost effectiveness | |
| Treatment patterns and outcomes among patients with skin and soft tissue infections in Belgium | ||||
| Kasem S Akhras, Erik Spaepen, Sanjay Merchant, Lieven Annemans | ||||
| ISPOR 2007 10th Annual European Congress |
||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Dermatology | 2007 | English | ||
| Cost-effectiveness of Darunavir/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings. | ||||
| Moeremans K, Annemans L, Smets E, Wyffels V, Lothgren M, Allegri G | ||||
| ISPOR 10th Annual European Congress, 2007, October 20-23, Dublin, Ireland |
||||
| , Oral presentation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , HIV AIDS | 2007 | English | , Cost effectiveness | |
| Cost-effectiveness of DRV/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings. | ||||
| Moeremans K, Annemans L, Smets E, Wyffels V, Wilson B, Lothgren M, Allegri G | ||||
| 11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain |
||||
| , Oral presentation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , HIV AIDS | 2007 | English | , Cost effectiveness | |
| A health economic evaluation of hexvix as adjunct to standard white light cystoscopy in the management of superficial bladder cancer | ||||
| Demarteau N, Braeckman J, Michielsen D, Sweet A, Zyczynski T, Lamotte M | ||||
| ISPOR 2007 10th Annual European Congress |
||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2007 | English | ||
| Adjuvant trastuzumab treatment in early stage breast cancer: cost-effectiveness in the Belgian healthcare setting | ||||
| Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, Nechelput M, Delabaye I, Gyldmark M, Annemans L | ||||
| ISPOR 2007 10th Annual European Congress |
||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2007 | English | , Cost effectiveness | |
| A health economic evaluation of concomitant surgical ablation for atrial fibrillation. | ||||
| Lamotte M, Annemans L, Bridgewater B, Kendall S, Siebert M | ||||
| Eur J Cardiothorac Surg., 2007, 32(5): 702-710 |
||||
| , Article | ||||
| , Belgium | ||||
| Abstract: http://ejcts.ctsnetjournals.org/cgi/content/abstract/32/5/702 | ||||
| Condition | Year | Language | Analysis type | |
| , Surgery | 2007 | English | , Economic evaluation | |
| Economic evaluation of the fentanyl HCL patient-activated transdermal system (ITS) in acute post-operative pain management (POPM) in Belgium. | ||||
| Annemans L, Hunsche E, Spaepen E, Van Bellinghen LA, Choe Y, Kavanagh S | ||||
| 5th Congress of the European Federation of IASP Chapters (EFIC), 2006, September 13-16, Istanbul, Turkey |
||||
| , Abstract | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Surgery | 2006 | English | , Economic evaluation | |
| Adjuvant trastuzumab treatment in early stage breast cancer: cost-effectiveness in the Belgian healthcare setting. | ||||
| Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, Nechelput M, Delabaye I, Gyldmark M, Annemans L | ||||
| Value in Health, 10(6): A336 |
||||
| , Oral presentation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2006 | English | , Cost utility | |
| Costs and outcomes of noscomial pneumonia in a sample of Belgian hospitals. | ||||
| Spaepen E, Merchant S, Neslusan C, Annemans L | ||||
| ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Respiratory disease | 2006 | English | , Burden of illness | |
| [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease] | ||||
| Lamotte M, Pinol C, Brotons C, Annemans L, Guardiola E, Evers T, Kubin M | ||||
| Rev Esp Cardiol., 2006, 59(8): 807-815 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2006 | Spanish | , Economic evaluation | |
| A health economic evalutation of aspirin in the primary prevention of cardiovascular disease. | ||||
| Lamotte M, Annemans L, Evers T, Kubin M, Hu S | ||||
| ISPOR 2nd Asia-Pacific conference, Shanghai, China |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2006 | English | ||
| A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. | ||||
| Lamotte M, Annemans L, Evers T, Kubin M | ||||
| Pharmacoeconomics, 2006, 24(2): 155-169 Pharmacoeconomics; 24:155-69 |
||||
| , Article, Manuscript in preparation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease, Health economics | 2006 | English | , Economic evaluation | |
| A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. | ||||
| Lamotte M, Annemans L, Kawalec P, Zoellner Y | ||||
| Pharmacoeconomics, 2006, 24(8): 783-795 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2006 | English | , Economic evaluation | |
| Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. | ||||
| Annemans L, Lamotte M, Kubin M, Evers T, Verheugt FW | ||||
| Int J Clin Pract., 2006, 60(9): 1129-1137 |
||||
| , Article | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Cardiovascular disease | 2006 | English | , Economic evaluation | |
| Medical management and costs associated with staphylococcus aureus (SA) bacteraemia in haemodialysis patients: A cost-of-illness study. | ||||
| Strens D, Moeremans K, Annemans L, Jadoul M, Cambier P, Billiouw JM | ||||
| ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark |
||||
| , Oral presentation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Diabetes | 2006 | English | , Cost of illness | |
| An observational health-economic analysis of the treatment of patients with voriconazole in a real-life setting | ||||
| Van Campenhout H, De Mees V, Marbaix S, Annemans L | ||||
| |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics | 2006 | English | ||
| Assessment of the economic value of the INTERCEPT Blood System in Belgium. | ||||
| Moeremans K; Annemans L. | ||||
| Transfusion Medicine, 2006; 16:17-30 |
||||
| , Manuscript in preparation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Health economics | 2006 | English | ||
| Assesment of the economic value of the INTERCEPT blood system in Belgium. | ||||
| Moeremans K, Warie H, Annemans L | ||||
| Transfus Med.; 16:17-30 |
||||
| , Manuscript in preparation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Hematology | 2006 | English | ||
| A cost-consequence analysis of darbepoetin alfa administered every 3 weeks (Q3W_DA) compared to weekly epoetin alfa (QW_EA) or epoetin beta (WQ_EB) in patients with chemotherapy-induced anemia (CIA): A retrospective study. | ||||
| Van Bellinghen LA, Demarteau N, Annemans, Bracco A | ||||
| ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2006 | English | , Cost consequence | |
| An update: Health economics of managing multiple myeloma | ||||
| K Moeremans, L Annemans. | ||||
| European Journal of Cancer, 2006; 42(11):1684-96 |
||||
| , Manuscript in preparation | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2006 | English | ||
| Treatment of actinic keratosis (AK) and basal cell carcinoma (BCC) with Metvix® (MAL-PDT) in real life practice: a cost of illness and model validation study. | ||||
| Caekelbergh K1, Annemans L1 | ||||
| 1 IMS Health, Brussels, Belgium | ||||
| ISPOR 9th Annual European Congress, 2006, October 29-31, Copenhagen, Denmark |
||||
| , Poster | ||||
| , Belgium | ||||
| Condition | Year | Language | Analysis type | |
| , Oncology | 2006 | English | , Cost of illness | |